From: What is the impact of endometriosis and the AFS stage on cumulative pregnancy rates in IVF programs?
 | Group A | Group B | Group C | Group D | Group E | p |
---|---|---|---|---|---|---|
N cycles | 430 | 460 | 56 | 88 | 316 | Â |
IVF and ICSI (%) | 30.2/69.8 | 45.2/54.8 | 25.2/74.8 | 52.2/47.8 | 46.8/53.2 | ***A–B, A–D, B–C, C–D, C–E |
Cycle rank (n) | 1.6 ± 0.9 | 1.6 ± 0.9 | 1.6 ± 0.9 | 1.5 ± 0.9 | 1.6 ± 0.9 |  |
Antagonist (%) | 86.9 | 83.0 | 85.7 | 84.0 | 82.2 | Â |
Short agonist (%) | 3.7 | 6.9 | 10.7 | 6.8 | 6.3 | *B–C, C–D; **A–D, C–E; ***A–B, A–C |
Long agonist (%) | 9.4 | 10.1 | 3.6 | 9.2 | 11.5 | ***A–C, B–C, C–D, C–E |
Initial FSH dose (IU/day) | 272 ± 111 | 303 ± 123 | 272 ± 132 | 327 ± 114 | 303 ± 116 | *C–D; ***A–B |
Total FSH dose (IU) | 2688 ± 1011 | 3059 ± 1506 | 2795 ± 1546 | 3329 ± 1344 | 3032 ± 1327 | *C–D; ***A–B |
E2 on dhCG (pg/mL) | 2108 ± 1248 | 1916 ± 1173 | 2272 ± 754 | 1703 ± 1162 | 1913 ± 1229 | *A–B, A–E; **A–D, B–C, C–E; ***C–D |
LH on dhCG (IU/L) | 3.3 ± 2.3 | 2.7 ± 2.1 | 2.0 ± 1.2 | 2.8 ± 2.2 | 2.8 ± 2.1 | **A–E, C–D; ***A–B, A–C, B–C, C–E |
P on dhCG (ng/mL) | 0.9 ± 0.4 | 0.9 ± 0.4 | 0.8 ± 0.1 | 1.0 ± 0.2 | 0.9 ± 0.3 |  |
Endometrium thickness (mm) | 9.6 ± 2.0 | 9.6 ± 1.9 | 10.5 ± 1.7 | 9.7 ± 1.3 | 9.5 ± 2.3 | **C–D; ***A–C, B–C, CE |
Sperm count (×106/mL) | 36.4 ± 27.1 | 54.6 ± 42.5 | 36.6 ± 21.7 | 93.0 ± 44.0 | 46.3 ± 29.8 | **B–E, C–E; ***A–B, A–D, B–C, B–D, C–D, D–E |